For instance, a powdered pomegranate extract rich in ellagitannins—derived from peels and standardised to contain 37% ellagitannins (as punicalagin) and 3.5% free ellagic acid—significantly inhibited proliferation and reduced HIF-1α and VEGF levels in prostate cancer cells (LNCaP) and HUVECs under hypoxic conditions in vitro. Here, VEGFA is linked to prostate cancer.